Fresenius Group Overview

The Health Care Group
Stories
Archive „Stories“
Investors
Contact

Fresenius SE & Co. KGaA

Investor Relations

+49 (0) 6172 608-2485
ir-fre@fresenius.com
Media
- News
- Social Media
- Calendar
- Contacts
- Media Center
Contact

Matthias Link

Senior Vice President Corporate Communications

T: +49 (0) 6172 608-2872
matthias.link@fresenius.com
Careers
Menu
Filter results
- Chapter
- Format
  - Website (0)
  - PDF (0)
Share
- Facebook
- Twitter
- LinkedIn
- Xing
- Google+
- E-Mail
Services
- Deutsch
- Print
- Contact
- RSS

Investors

Fresenius Investment Highlights

Diversified revenue and earnings base with four strong business segments
Leading positions in non-cyclical markets with predictable growth
Industry-leading organic growth in all business segments
Strong earnings performance and cash flow generation
Attractive shareholder returns
Prudent financial management

"Our businesses developed solidly in the third quarter, keeping Fresenius on track to deliver the results that we promised earlier this year. We posted strong organic growth across all four business segments."

(Stephan Sturm, Chairman of the Management Board)

NEXT EVENT

February 20, 2020 | Bad Homburg, Germany

Conference Call Full Year Results 2019, Fresenius

Live Webcast

Import (ICS)

NEXT EVENT

News

Brief News
Fresenius Kabi enters into joint venture to advance new cell and gene therapies

Fresenius Kabi, Bio-Techne and Wilson Wolf have formed a new joint venture to support researchers and biopharmaceutical companies in the field of cell and gene therapy. The joint venture is owned equally by the three partners and will focus on providing scalable manufacturing technologies and processes needed to develop and commercialize new cell and gene therapies. No other financial terms were disclosed.

January 21, 2020Fresenius Kabi

Brief News
Fresenius Helios trains doctors in antibiotics management

Fresenius Helios has started training experts in antibiotics management to combat the growing threat from multi-resistant bacteria. In the coming years, more than 600 doctors will be trained at the company’s 86 hospitals in Germany on the correct way to handle antibiotics. These doctors will raise awareness of the problem among colleagues and be available for consultations with them. In addition, Fresenius Helios is introducing a system under which each hospital will report on its antibiotics usage.

January 16, 2020Fresenius Helios
Fresenius successfully places bonds with a volume of 750 million euros

January 07, 2020Fresenius

Fresenius Helios acquires leading private hospital in Colombia

December 23, 2019Fresenius Helios
Brief News
Fresenius Kabi launches IV Drug in the U.S.

Busulfan, a drug for certain blood cancers, expands the company’s broad oncology portfolio.

December 20, 2019Fresenius Kabi

Brief News
Fresenius Kabi launches IV Drug in the U.S.

Dicyclomine Hydrochloride Injection, an antispasmodic agent, expands Fresenius Kabi’s large and growing generic critical care portfolio.

December 19, 2019Fresenius Kabi
Brief News
Fresenius Kabi launches IV Drug in the U.S.

Ertapenem, an antibiotic, expands Fresenius Kabi's anti-infective portfolio.

December 11, 2019Fresenius Kabi

Brief News
Fresenius Helios awards new innovation prize

Fresenius Helios has awarded its inaugural Helios-Pro-Inno Prize for outstanding innovation and projects in patient care and hospital management. Three different projects at Helios Wuppertal, Helios Berlin-Buch and Helios Bad Saarow hospitals in Germany were honored: A color and lighting concept that demonstrably improved the well-being of intensive care patients and even reduced their need for certain medications; the appointment of a “Feel Good Manager” for resolving employees’ problems in the workplace, and an antibiotics reporting system developed in response to the growing threat from multi-resistant bacteria. A jury of eight members, from different occupational groups, chose the Helios-Pro-Inno Prize winners from more than 70 entries.

December 10, 2019Fresenius Helios
Brief News
Fresenius Kabi launches IV Drug in the U.S.

Fosaprepitant, an antiemetic, expands the company's large sterile injectable portfolio in oncology.

November 13, 2019Fresenius Kabi

Brief News
Fresenius Vamed completes main university hospital building in Lübeck

After four years of construction Fresenius Vamed has completed the new main building at University Hospital Schleswig-Holstein (UKSH) in Lübeck. Following the opening in August of the new main building at the UKSH’s other location, in Kiel, the modernization of Germany’s second-largest university hospital is now largely complete. In addition to the new construction and the comprehensive renovation of the two university hospital locations, the project includes their technical management through 2044. With a total volume of €1.7 billion, the UKSH modernization is currently the biggest public-private partnership project in Europe’s healthcare sector.

November 12, 2019Fresenius Vamed
Brief News
Fresenius Vamed wins awards for spa and wellness facilities

VAMED Vitality World has been named the “World’s Best Thermal Spa & Medical Wellness Operator 2019” at the World Spa Awards. Four VAMED Vitality World facilities – Geinberg5 Private Spa Villas, St. Martins Therme & Lodge, Therme Laa Hotel & Spa and la pura women’s health resort – also won in their individual categories. VAMED Vitality World, part of Fresenius Vamed, operates a total of nine spa and health resorts in Austria.

November 05, 2019Fresenius Vamed

Fresenius Helios acquires medical diagnostics provider in Colombia

November 04, 2019Fresenius Helios
Fresenius confirms guidance after solid third quarter

October 29, 2019Fresenius

Brief News
Fresenius Kabi launches new Heparin Sodium in prefilled syringe in the U.S.

A new presentation of Fresenius Kabi Heparin is now available in the company’s Simplist^® ready-to-administer prefilled syringe, expanding the company's Heparin portfolio.

October 25, 2019Fresenius Kabi
Brief News
Fresenius Kabi expands plant in Brazil

Fresenius Kabi has completed the expansion of its plant in Aquiraz, Brazil, increasing the facility’s capacity for parenteral nutrition production by around 30 percent. The company expects to hire about 50 new employees to bring the plant’s workforce to about 850. Fresenius Kabi, which has been active in Brazil for more than 40 years, invested some €20 million in the expansion and modernization of the Aquiraz plant.

October 23, 2019Fresenius Kabi

Brief News
Fresenius Kabi launches Fulvestrant in prefilled syringes in the U.S.

Fulvestrant Injection is now available in the United States in the company’s ready-to-administer prefilled syringes and is the latest addition to Fresenius Kabi’s broad oncology portfolio. The product is the only room temperature stable Fulvestrant Injection currently available in the U.S.

October 07, 2019Fresenius Kabi
Brief News
Fresenius Helios develops system to measure patient safety

Fresenius Helios has developed a new system for measuring patient safety, and is introducing it in all 86 Helios hospitals across Germany. The new system will complement the company’s existing quality management system and combine internationally established patient safety indicators with various indicators that Helios has developed through clinical practice. These include measurements on such indicators as false diagnoses, medication errors and patient falls. When Helios begins reporting the results next year, it will be the first German hospital operator to provide patient safety data that can be compared internationally.

September 18, 2019Fresenius Helios

Brief News
Fresenius Kabi opens research and development center for biosimilars in Switzerland

Fresenius Kabi has opened a new research and development center for biosimilars in Eysins, in the Swiss canton of Vaud. The facility, in which the company invested about €15 million, will strengthen Fresenius Kabi’s capability to develop new biosimilars, particularly in the areas of autoimmune diseases and oncology. A biosimilar is a drug that is “similar” to another, already approved biologic drug. More than 100 employees representing over 20 nationalities work at the Eysins site, and the company plans to expand the workforce in the near future.

September 18, 2019Fresenius Kabi
Brief News
Fresenius SE & Co. KGaA included in Dow Jones Sustainability Index

Fresenius will be included in the Dow Jones Sustainability Index Europe (DJSI Europe) for the first time as from 23 September 2019. The selected companies must demonstrate continuous improvement with regard to sustainability and are assessed by analysts from asset manager RobecoSAM.

September 17, 2019Fresenius

Brief News
2020 DRG inflator for German hospitals set at 3.66%

The price increase for hospital services in Germany has been set at 3.66% for 2020. As it is subject to negotiations at the state level as well as individual hospital discounts, the final price increase on the individual hospital level will, however, be lower.

September 16, 2019Fresenius Helios
Brief News
Fresenius Helios launches digital portal for patients

Fresenius Helios patients in Germany can soon start accessing letters from their doctors, test results and other medical documents over an online platform – the Helios Patients Portal. This new portal can also be used to make appointments. The confidentiality of patient data is assured through the use of two-factor authentification. All 86 of the company’s hospitals, 126 medical care centers and eight prevention centers throughout Germany are being gradually linked to the Helios Patients Portal. The company is also developing a portal for doctors.

September 11, 2019Fresenius Helios

Fresenius Helios acquires two hospitals in Colombia

September 03, 2019Fresenius Helios
Brief News
Fresenius Kabi launches IV Drug in the U.S.

Phenylephrine Hydrochloride Injection is the latest addition to the company´s growing anesthesia and analgesia portfolio.

August 30, 2019Fresenius Kabi

Brief News
Fresenius Vamed completes main university hospital building in Kiel

After four years of construction Fresenius Vamed has completed the new main building at University Hospital Schleswig-Holstein (UKSH) in Kiel. The completion marks the first milestone in the modernization of Germany’s second-largest university hospital, with the main building of the Lübeck location scheduled to open in November. The project includes new construction and the comprehensive renovation of the two university hospital locations, some 80 kilometers (50 miles) apart in Schleswig-Holstein state, and their technical management through 2044. With a total volume of €1.7 billion, the UKSH’s modernization is currently the biggest public-private partnership project in Europe’s healthcare sector.

August 20, 2019Fresenius Vamed
Brief News
Fresenius Helios expands preventive medicine offering

Fresenius Helios has opened a new Helios Prevention Center in Berlin, as the company continues the expansion of its occupational medicine activities into a standalone business area. The modern, 440-square-meter (4,700-square-foot) center in the heart of Germany’s capital offers comprehensive check-ups from a single source. HCP patients are accompanied throughout the check-up by their own personal physician, and do not have to search for the right department for their next test, deal with different contact persons, or face long waiting times. And if a test turns up something requiring medical treatment, the patient has direct access to the Helios healthcare network and an exclusive hotline for making appointments with specialists.

August 05, 2019Fresenius Helios

Fresenius raises Group sales growth guidance after good second quarter

July 30, 2019Fresenius
Brief News
Fresenius Kabi launches IV Drug in the U.S.

Fresenius Kabi launches Levothyroxine Sodium Injection in the U.S. It is the first, and only, pre-mixed solution of this medication currently available in the U.S.

July 08, 2019Fresenius Kabi

Brief News
Fresenius Kabi launches IV Drug in the U.S.

Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection is the latest addition to the company´s growing anesthesia and analgesia portfolio.

June 19, 2019Fresenius Kabi
Brief News
Fresenius Kabi launches Neostigmine in prefilled syringes in the U.S.

Neostigmine is now available in the company’s Simplist® ready-to-administer prefilled syringes, expanding the company´s analgesia and anesthesia portfolio.

June 11, 2019Fresenius Kabi

Brief News
S&P upgrades Fresenius to BBB with stable outlook

Standard & Poor’s has revised Fresenius’ corporate credit rating to BBB with a stable outlook from BBB- with a positive outlook. Fresenius is rated investment grade by the three leading rating agencies Standard & Poor’s (BBB/stable), Moody's (Baa3/stable) and Fitch (BBB-/stable).

May 23, 2019Fresenius

Disclaimer All News

Library

All Financial Reports

Information & Order Service

Stay informed about the latest news and developments at our Group by subscribing to our Investor News and/or to the Fresenius Brief News. These services are free of charge and may be cancelled at any time.

I am a private investor I am an institutional investor

Title *

First name * Please enter your first name.

Last name * Please enter your last name.

Company * Please enter your company.

Department * Please enter your department.

Job function *

Please enter your function.

Street / Number * Please enter your street.

Postal Code / City * Please enter your postal code and city.

Country *

E-mail * Please enter your e-mail address.

Telephone number

All fields marked with * are required.

Please send me via email

Fresenius Brief News German English

Fresenius Investor News German English

Do you have other questions or need any more information?
Please send us a message:

To unsubscribe to these services, please send a brief e-mail to ir-fre@fresenius.com or call +49 (0) 6172 608-2470.

Follow us

The Health Care Group

Contact us

Fresenius SE & Co. KGaA
Else-Kröner-Str. 1
61352 Bad Homburg v.d.H.
Germany
T +49 (0) 6172 608-0
pr-fre@fresenius.com

Contact

Visit us